Haiyan Xu

TL;DR: The 3-month formulation of paliperidone palmitate administered 4 times yearly significantly delayed time to relapse in patients with schizophrenia and has a safety profile consistent with other marketed palipersidone formulations.

TL;DR: Treatment with paliperidone palmitate (100 mg eq.) was efficacious and all doses tested were tolerable, and significant improvement in the Personal and Social Performance score from baseline to endpoint versus placebo.

TL;DR: PP3M was noninferior to PP1M: relapse rates were similar in both groups and increased weight was the most common treatment-emergent adverse event (double-blind phase; 21% each).

TL;DR: It is found that administration of either 1- or 3-monthly long-acting injectable antipsychotics not only eased the burden of daily dosing and patient compliance, but also had a positive impact on the stress conditions of caregivers.

TL;DR: To assess the tardive dyskinesia (TD) rate in studies of once‐monthly long‐acting injectable (LAI) paliperidone palmitate and once‐daily oral palipersidone extended release (Pali ER), a large number of animals were randomly allocated to receive either the LAI or the oral version.